PROJECT

Projects

Environmental & Social Review Summary

Project Number

45947

Company Name

AVACARE GLOBAL

Date ESRS Disclosed

Apr 30, 2022

Country

Africa Region

Region

Africa

Last Updated Date

Sep 14, 2022

Environmental Category

B - Limited

Status

Active

Previous Events

Approved : Jun 10, 2022
Signed : Jun 13, 2022
Invested : Sep 12, 2022

Sector

other

Industry

other

Department

Regional Industry - MAS Africa

Project Description

Avacare Global (“Avacare” or the “company”) is an integrated distributor and manufacturer of pharmaceutical and healthcare consumable products in Sub-Saharan Africa (www.avacarehealth.com). Founded in 1996, the company currently operates 25 warehousing and 15 manufacturing facilities across 18 African countries including South Africa, Namibia, Botswana, Zimbabwe, eSwatini, Lesotho, Zambia, and Kenya. Avacare is also involved in healthcare training and education through Intellectus Campus. In view of the growing demand for pharmaceutical products and consumables, the company is looking to expand their operations, both organically and through acquisitions, into East and Francophone Africa while continuing to consolidate their position in existing markets.

To support entry into these markets, IFC is proposing approximately US$48.6 million financing package comprised of: (i) approximately US$28.6 million equity investment; and ii) approximately US$20 million of a secured ‘A’ Loan. Funds will be utilized across the Avacare group, including its subsidiaries, as capital to allow for the anticipated growth. The investment will be a part of IFC’s Global Health Platform as it will support the distribution and manufacturing of essential COVID-19 related vaccines and personal protective equipment across Africa.

Overview of IFC's Scope of Review

IFC’s appraisal focused on the review of the company’s existing environmental and social management system (ESMS), policies, procedures, management plans, as well as existing management capacity vis à vis the inherent risks for the sector and the contextual risks of the market where the company operates. The environmental and social (E&S) review was conducted through conference calls in February 2022 and included engagement with the Group Human Resources (HR) executive, the Group Head of Mergers and Acquisitions, and the Group Head: Environmental, Health and Safety (EHS). These discussions were supported by site visits to key operations based in Cape Town, South Africa, including Afrigen Biologics and Vaccines, Supra Healthcare Manufacturing, and Barrs Pharmaceuticals. The appraisal will be supplemented by further site visits to key manufacturing and warehousing sites when travel restrictions are fully lifted, and the ESRS/ESAP will be updated as necessary.

E & S Project Categorization and Applicable Standard

Environmental and Social Mitigation Measures

Stakeholder Engagement

Broad Community Support

Environmental & Social Action Plan